Cargando…
The Role of Atypical Cannabinoid Ligands O-1602 and O-1918 on Skeletal Muscle Homeostasis with a Focus on Obesity
O-1602 and O-1918 are atypical cannabinoid ligands for GPR55 and GPR18, which may be novel pharmaceuticals for the treatment of obesity by targeting energy homeostasis regulation in skeletal muscle. This study aimed to determine the effect of O-1602 or O-1918 on markers of oxidative capacity and fat...
Autores principales: | Simcocks, Anna C., O’Keefe, Lannie, Jenkin, Kayte A., Cornall, Lauren M., Grinfeld, Esther, Mathai, Michael L., Hryciw, Deanne H., McAinch, Andrew J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460607/ https://www.ncbi.nlm.nih.gov/pubmed/32824681 http://dx.doi.org/10.3390/ijms21165922 |
Ejemplares similares
-
Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity
por: Simcocks, Anna C, et al.
Publicado: (2019) -
CB(1) Ligand AM251 Induces Weight Loss and Fat Reduction in Addition to Increased Systemic Inflammation in Diet-Induced Obesity
por: O’Keefe, Lannie, et al.
Publicado: (2022) -
Treatment of Diet-Induced Obese Rats with CB(2) Agonist AM1241 or CB(2) Antagonist AM630 Reduces Leptin and Alters Thermogenic mRNA in Adipose Tissue
por: O’Keefe, Lannie, et al.
Publicado: (2023) -
Fatty Acid Modulation of the Endocannabinoid System and the Effect on Food Intake and Metabolism
por: Naughton, Shaan S., et al.
Publicado: (2013) -
Editorial: Peripheral Regulators of Obesity
por: McAinch, Andrew J., et al.
Publicado: (2019)